

# ■ | Scientific program – 05.12.2024

## Thursday, December 5

from 08.00	Door opening Networking Area	Foyer
08.30–08.45	<b>Opening &amp; Welcome Address of the 56th Annual Meeting of the Swiss Society of Nephrology</b>	<b>Room Singapore</b>
08.45–09.30	<b>State of the Art Lecture 1:</b> Artificial Intelligence in Nephrology Prof. Ingeborg Bajema, Groningen (NL)	<b>Room Singapore</b>
09.30–10.10	<b>Short Oral Presentations Session 1</b>	<b>Room Singapore</b>
09.32/OC 31	FGF23 drives leukocyte migration to the kidney in glomerular disease	*Matthias B. Moor, Stockholm (SWE)
09.37/OC 43	Population genetics meets precision-cut kidney slices: Nephrotoxicity modelled ex vivo in the founder strains of the BXD mouse consortium	*Matthias B. Moor, Stockholm (SWE)
09.42/OC 29	Elucidating the effects of sex, age and genetic variation on renal cell composition in two related genetically diverse mouse populations	*Matthias B. Moor, Stockholm (SWE)
09.47/OC 53	Tocilizumab Reduces Injury-Repair-Associated Transcripts Compared to Standard Immunosuppression in Chronic-Active Antibody-Mediated Rejection	Kai Castrezana Lopez, Zürich
09.52/OC 42	Non-HLA antibodies in the diagnosis of antibody-mediated rejection without circulating HLA donor-specific antibodies: biopsy-based transcript diagnostics perspective	*Dusan Harmacek, Zürich
09.57/OC 49	Successful use of mycophenolate mofetil (MMF) in the treatment of acute checkpoint inhibitor-induced interstitial nephritis	*Stephanie Zappi, Basel

\* = YSN submission

## Thursday, December 5

10.02/OC 27	cFGF23 alleviates kidney inflammatory pathways induced by sustained FGF23 signaling	Ganesh Pathare, Zürich
10.07/OC 32	Gastric bypass-induced weight loss restores aldosterone reactivity to orthostatic stress in obese patients	Joachim Zahnd, Lausanne
09.30–10.10	<b>Short Oral Presentations Session 2</b>	<b>Room Sydney</b>
09.32/OC 45	Social media call to search for an altruistic kidney donor: ethical or not	*Nathalie Hammer, Bern
09.37/OC 40	Membranous nephropathy secondary to graft-versus-host disease following hematological stem cells transplant	Antonio Ulpiano, Riviera-Chablais
09.42/OC 39	Longitudinal donor-derived cell-free DNA measurements of stable kidney transplant recipients for improving allograft health	Fanny Sandberg, Bern
09.47/OC 50	The dilemma of CKD and ESKD following pre-eclampsia: a literature review and meta-analysis	*Gaia Bianchi, Bern
09.52/OC 33	Glomerulonephritis associated with acute human Parvovirus B19 infection: a report of 5 cases and a review of the literature	*Ophélie Théraulaz, Fribourg
09.57/OC 47	Structure and function analysis of NPHS1 and NPHS2 missense variants	Blanda Beci, Zürich
10.02/OC 28	early-stage antibody-mediated rejection: biopsy-based-transcript-diagnostics predict proteinuria in cases with subclinical donor-specific antibodies	*Annina Baumgartner, Zürich
10.07/OC 56	Usability of Machine Learning Algorithms based on Electronic Health Records for the Prediction of Acute Kidney Injury and Transition to Acute Kidney Disease: a Proof of Concept Study	Antonio Bellasi, Lugano

\* = YSN submission



## Thursday, December 5

09.30–10.10	<b>Elevator Pitch, Phase 1: all authors</b>	<b>Room Rio</b>
09.36/OC 57	A critical appraisal of current criteria to diagnose the syndrome of inappropriate antidiuresis (SIAD)	Florian Buchkremer, Aarau
09.38/OC 74	Unexpected proteinuria in a patient with alkaptonuria	* Céline Tümay, Basel
09.40/OC 58	Aurantiasis cutis in a 60-year-old patient undergoing dialysis	* Agnes Kneubühl, Lachen
09.42/OC 59	Bicentric validation of the diffusion-weighted magnetic resonance imaging as a noninvasive tool to assess fibrosis level	* Aurélie Huber, Genève
09.44/OC 71	T1 mapping magnetic resonance imaging predicts renal function decline	* Aurélie Huber, Genève
09.46/OC 60	Cobalamin C deficiency associated atypical HUS	* Martha Stampfli, Bern
09.48/OC 75	unlocking kidney protection: the antiproteinuric impact of sglT2 inhibitors in transplant recipients	* Brian Lauener, Bern
09.50/OC 62	early onset end-stage renal disease in a patient with a pkd2 deletion	Antonio Bellasi, Lugano
09.52/OC 63	High level of psychosocial distress in a dialysis population: A single center cross-sectional observation. Time for an integrated nephropsychological service?	Yvonne Holzmann, Liestal
09.54/OC 64	Mimicry and mystery – subacute kidney failure in a man with lymphadenopathy	Max Schünemann, Basel
09.56/OC 72	The price of beauty	Argyrios Georgalis, Chur
09.58/OC 76	Zoo in the belly – a furry cause of peritoneal dialysis (PD) peritonitis	Shuyang Traub, Basel
10.00/OC 66	Patients' quality of life and care satisfaction on a Swiss dialysis ward	* Petra Meury, Basel
10.02/OC 68	Primary aldosteronism unmasked by pregnancy: a challenging management and diagnosis	* Domenico Cozzo, Lugano
10.04/OC 69	Primary membranoproliferative glomerulonephritis (MPGN): natural history, complement system and renal outcome	* Giliane Nanchen, Lausanne

\* = YSN submission

## Thursday, December 5

10.06/OC 70	Renal handling of Selenium and Manganese in persons with and without chronic kidney disease and their associations with renal tissue oxygenation and yearly decline of renal function	*Walid Ameur, Lausanne
10.08/OC 73	the spectrum and characteristics of acute renal dysfunction at the university hospital basel	*Carole Lippuner, Basel
10.10/OC 65	Osmotic nephropathy secondary to L-proline-stabilized intravenous immunoglobulins	Antonio Ulpiano, Riviera-Chablais
10.12/OC 61	Deconvoluting the distal convoluted tubule – a mouse population genetics approach	*Matthias B. Moor, Stockholm (SWE)
10.14/OC 67	Plasma-derived Fetuin-A as a potential patient-specific biomarker for predicting acute kidney injury associated with cardiovascular surgery: interim analysis results from the PEAK study	*Nathalie Hammer, Bern
Followed by	Presentation rating by the audience	
Followed by	Phase 2: 3 selected long presentations	
10.10–10.20	Short break	Foyer
10.20–11.00	<b>Short Oral Presentations Session 3 Room Singapore</b>	
10.22/OC 48	Successful Targeting of the Alternative Complement Cascade with Iptacopan for the Treatment of IgA Nephropathy: A Case Report	*Leonore Ingold, Basel
10.27/OC 35	Impact of pre-implantation hernia screening in peritoneal dialysis patients on hernia surgery during dialysis	Katrin König, Liestal
10.32/OC 34	impact of covid-19 pandemic restrictions on hypertensive disorders of pregnancy according to country income levels: a systematic literature review	*Antonia Zucchelli, Bülach

\* = YSN submission



## Thursday, December 5

10.37/OC 25	Biopsy-based transcript diagnostics show an early molecular AMR signature in cases with probable AMR independent from the individual active histological lesions	* Hasibullah Ehsas, Zürich
10.42/OC 55	TrkC Deficiency in Nephrons Exacerbates Tubular Kidney Injury in Mice.	Carolin Eul, Zürich
10.47/OC 51	The nephrin-associated phospho-protein network is essential for filtration at the slit diaphragm.	Luisa Bertgen, Zürich
10.52/OC 52	Time is kidney – Acute renal artery syndrome as a rare cause of high blood pressure	* Stefan Zschiedrich, Solothurn
10.57/OC 30	Endo-lysosomal deacidification links disordered protein handling and lipid metabolism in kidney tubules	Imene Sakhi, Zürich
10.20–11.00	<b>Short Oral Presentations Session 4</b>	<b>Room Sydney</b>
10.22/OC 36	Impact of Repeated Non-fatal Infectious Events on Patient and Graft Outcome in ABO Incompatible Living Donor Kidney Transplantation	* Federica Bocchi, Paris (Frau)
10.27/OC 46	Sparsentan vs irbesartan in patients with immunoglobulin A nephropathy (IgAN): Subgroup analyses of 2-year results from the pivotal Phase 3 PROTECT trial	Stéphane Genoud, Villars-sur-Glâne
10.32/OC 38	Kidney transplantation in combination with RNAi therapy (lumasiran) instead of combined liver transplantation for primary hyperoxaluria type 1 – a case report	Alexander Ritter, St. Gallen
10.37/OC 26	Cell fate determination of directly reprogrammed mouse and human kidney cells	* Ruth Röck, Zürich
10.42/OC 37	Injury- and rejection-associated transcripts are linked to short-term functional outcomes in belatacept late conversion: Providing insights beyond histological categorization	* Lukas Weidmann, Zürich

\* = YSN submission



## Thursday, December 5

10.47/OC 44	Safety and effectiveness of prolonged calcineurin inhibitor-exposure during belatacept late conversion	* Lukas Weidmann, Zürich
10.52/OC 41	Molecular rejection phenotype scores predict kidney allograft loss and eGFR decline along the AMR continuum	* Lukas Weidmann, Zürich
10.57/OC 54	Transcriptomic analysis of kidney allograft biopsies may allow early detection of rejection, precise rejection typing, and dynamic treatment monitoring	* Lukas Weidmann, Zürich
11.00–11.30	Coffee break – Visit of the exhibition	Foyer
11.30–12.15	<b>Parallel Symposium:</b> Sponsored by Otsuka Lupus Nephritis: Treatment guidelines and options, with recent examples from the clinic	<b>Room Singapore</b>
11.30–12.15	<b>Parallel Symposium:</b> Sponsored by CSL Vifor New strategies and perspectives on managing IgA nephropathy. First experience with dual endothelin angiotensin receptor antagonist	<b>Room Sydney</b>
12.15–13.00	<b>State of the Art Lecture 2:</b> HLA Epitope Matching. New approaches for new organ allocation strategies Dr. Gideon Hönger, Basel Prof. Stefan Schaub, Basel”	<b>Room Singapore</b>
11.30–12.15	<b>Parallel Symposium:</b> Sponsored by Bayer (Schweiz) AG Finerenone – a therapeutic pillar for cardiorenal protection in patients with CKD and T2D – An interactive discussion on practical aspects of using Finerenone Tobias Breidthardt, Basel Grégoire Wuerzner, Lausanne Stefan Zschiedrich, Solothurn	<b>Room Sydney</b>
13.00–13.45	Lunch break – Visit of the exhibition	Foyer

\* = YSN submission



## Thursday, December 5

13.45–14.30	<b>State of the Art Lecture 3:</b> New Classification of GN Prof. Hans-Joachim Anders, München (DE)	<b>Room Singapore</b>
14.30–15.15	<b>Parallel Symposium:</b> OM Pharma Suisse SA Kidneys in Focus: Transforming Transplant Outcomes	<b>Room Singapore</b>
14.30	Introduction of the topic and goal of the meeting	Françoise-Isabelle Binet
14.35	Tacrolimus C/D rate importance in sensitive patients	Stefan Reuter
14.50	Tacrolimus in sensitive patients: what to care about?	Daniel Sidler
15.05	Discussions and closing remarks	Françoise-Isabelle Binet
14.30–15.15	<b>Parallel Symposium:</b> Sponsored by GSK Lupus Nephritis and SLE from the immunologist's point of view Prof. Dr. med Britta George, Zürich Prof. Dr. med. sc. Nat. Miro Räber, Zürich	<b>Room Sydney</b>
14.30	Introduction by Chair	Britta George
14.35	Lupus Nephritis and SLE from the immunologist's point of view	Miro Räber
14.50	Expert discussion Unifying forces: collaborative approaches in nephrology and immunology for SLE & lupus nephritis	Britta George Miro Räber
15.05	Closing remarks by Chair	Britta George
14.30–15.15	<b>SRRQAP – Swiss Dialysis Register</b>	<b>Room Rio</b>
15.15–15.25	Coffee break – Visit of the exhibition	Foyer
15.25–16.27	<b>Long Oral Presentations Session 1</b> Renal replacement therapy (hemodialysis and peritoneal dialysis)	<b>Room Singapore</b>
15.27/OC 4	CENSUS-EU: An observational study to investigate prevalence and burden of chronic kidney disease-associated pruritus in Europe	Fabienne Aregger, Bern

## Thursday, December 5

15.37/OC 15	Pattern Identification of Adverse Events to Predict Patient Trajectory during the First Two Years of Peritoneal Dialysis	Antonio Bellasi, Lugano
15.47/OC 16	Prediction of Peritoneal Dialysis Discontinuation at Two Years from Inception	Antonio Bellasi, Lugano
15.57/OC 11	Hypnosis can enhance ultrafiltration efficiency in hemodialysis: a preliminary experience and a systematic review of the literature	*Domenico Cozzo, Lugano
16.07/OC 1	Advance Care Planning with a Conversation Game: Quantitative Results of a Feasibility and Acceptability Study among dialysis patients in Geneva's nephrology unit	Anne Dufey Teso, Genève
16.17/OC 20	Survival of hemodialysis versus peritoneal dialysis patients: A Swiss perspective	Rebecca Guidotti, Zürich
15.25–16.27	<b>Long Oral Presentations Session 3</b> Clinical Nephrology	<b>Room Sydney</b>
15.27/OC 13	Impact of the legalization of medical aid in dying (MAID) in the management of stage 5 CKD: investigation in 3 French-speaking countries	Olivier Bonny, Fribourg
15.37/OC 10	FceRIneg dendritic cell 2 (DC2) subset accumulates in the urine of patients with nephrotic syndrome (NS) in complete remission: a potential role in the resolution of NS?	Diego De Haro, Lausanne
15.47/OC 8	Empagliflozin for urinary supersaturation reduction in non-diabetic patients with calcium and uric acid kidney stones: a randomized crossover, phase 2 trial (SWEETSTONE)	Simeon Schietzel, Bern
15.57/OC 3	Brain functional connectivity including the autonomous system is altered in hypertensive patients	Polona Pozeg, Lausanne

\* = YSN submission





## Thursday, December 5

16.07/OC 17	Projecting the Clinical and Environmental Burden of CKD in Switzerland until 2032 – the IMPACT-CKD model in action	Menno Pruijm, Lausanne
16.17/OC 14	kidney and skin involvement in levamisole-induced vasculopathy: a systematic review	*Martin Scoglio, Bern
16.27–17.27	<b>Long Oral Presentations Session 2</b> Basic Science	<b>Room Singapore</b>
16.27/OC 2	Aging uncovers the critical role of WDR72 for kidney function in mice	*Hannah Auwerx, Zürich
16.37/OC 21	Swiss Salt Study 2, second survey on salt consumption in Switzerland	Sonia Tassadit Chelbi, Lausanne
16.47/OC 18	Purinergic calcium signaling drives tubulo-interstitial crosstalk in kidney disease	Andreja Figurek, Zürich
16.57/OC 19	Single-nucleus analysis reveals excessive and adverse FGF23 effects in the distal nephron during early diabetic nephropathy	*Matthias B. Moor, Stockholm (SWE)
17.07/OC 12	Identification of a naturally derived senolytic compound to prevent kidney aging	Anna Rinaldi, Lugano
17.17/OC 23	Taurine Deficiency Is a Hallmark of Injured Kidney Allografts	Anna Rinaldi, Lugano
16.27–17.27	<b>Long Oral Presentations Session 2</b> Transplantation	<b>Room Sydney</b>
16.27/OC 5	Change of eplet verification status by using a novel adsorption/elution technique	*Tamara Buser, Muttenz
16.37/OC 24	Very long-term outcome of ABO incompatible kidney transplantation at the University Hospital Basel	*Céline Fontana, Basel
16.47/OC 7	Early complications in kidney donors and course of health-related quality of life 12 months after donation: An analysis of the Swiss Organ Living-Donor Health Registry	Patricia Hirt-Minkowski, Basel
16.57/OC 6	Combined molecular mismatch approaches to predict immunological events within the first year after renal transplantation	Cäcilia Jäger, Basel

\* = YSN submission

17.07/OC 22	Targeting CD38 in antibody-mediated rejection – the potential of noninvasive biomarkers to detect rejection reversal and recurrence	*Martina Schatzl, Wien (AUT)
17.17/OC 9	Evolution of outcomes and recipient age: what can we learn for future endpoint definitions in renal transplantation trials?	*Susanne Winkler, Basel
17.30–18.05	<b>Young Swiss Nephrology Award</b> Pecha Kucha presentations	<b>Room Singapore</b>
17.32/OC 77	Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.	*Matthias Diebold, Basel
17.40/OC 78	Practice patterns of routine blood sampling in Swiss hemodialysis centers	*Sophie Feuchter, Frauenfeld
17.48/OC 79	Renal cell carcinoma after kidney transplantation: observational cohort study from University Hospital Zurich	*Dusan Harmacek, Zürich
17.56/OC 80	Trough-level guided dosing is reliable for mycophenolate mofetil but not for enteric-coated mycophenolate sodium in kidney transplant recipients	*Susan Pfister, Zürich
starting 18.40	<b>Aperitif and Awards Ceremony at «Centro»</b>	<b>University Hospital Basel</b>
starting 20.00	<b>Galadiner at «Centro»</b>	<b>University Hospital Basel</b>

